Abstract CT155: Long term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma

Authors: Harshabad Singh, Kristen E. Lowder, Kevin Kapner, Ronan J. Kelly, Hui Zheng, Nadine J. McCleary, Thomas A. Abrams, Jennifer A. Chan, Eileen M. Regan, Samuel J. Klempner, Alison M. Hannigan, Lauren K. Brais, Elizabeth A. Andrews, Matthew B. Yurgelun, James M. Cleary, Douglas A. Rubinson, Lauren L. Ritterhouse, Garrett E. Maron, Andrew J. Aguirre, Lu Tan, Pan Du, Jeffrey A. Meyerhardt, Emma Gardecki, Jochen K. Lennerz, Shidong Jia, Brian M. Wolpin, Peter C. Enzinger

Published: 2023-04-14

DOI: 10.1158/1538-7445.am2023-ct155

Source: Full article